News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

3 Key Things Every CAR-T Investor Should Watch



7/25/2017 6:12:52 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
A long-awaited breakthrough in cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy, could finally hit the market later this year.

First-to-market advantage will likely to go Novartis (NYSE:NVS) with its drug named CTL019. Recently, a panel of FDA advisors unanimously recommended approval for CTL019, which will likely receive a final stamp of approval from the agency by early October. Other notable CAR-T players will be following closely behind, such as Kite Pharma (NASDAQ:KITE) and Juno Therapeutics (NASDAQ:JUNO) as a multi-billion dollar oncology market is up for grabs.

Read at Motley Fool


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES